Cubist Systematic Strategies, LLC Compugen LTD Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.75 - $2.95 $33,857 - $57,073	19,347 Added 169.7%	30,748 $79,000
Q4 2023 Feb 14, 2024	BUY	$0.53 - $2.0 $6,042 - $22,802	11,401 New	11,401 $22,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.38 $10,840 - $26,244	19,018 New	19,018 $21,000
Q2 2022 Aug 15, 2022	SELL	$1.57 - $3.33 $113,159 - $240,013	-72,076 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.76 - $4.64 $67,639 - $113,712	-24,507 Reduced 25.37%	72,076 $232,000
Q4 2021 Feb 14, 2022	SELL	$4.09 - $7.16 $2,368 - $4,145	-579 Reduced 0.6%	96,583 $415,000
Q3 2021 Nov 15, 2021	SELL	$5.8 - $8.02 $164,691 - $227,727	-28,395 Reduced 22.62%	97,162 $580,000
Q2 2021 Aug 16, 2021	BUY	$6.87 - $9.16 $156,848 - $209,131	22,831 Added 22.23%	125,557 $1.04 Million
Q1 2021 May 17, 2021	SELL	$7.67 - $13.77 $184,655 - $331,512	-24,075 Reduced 18.99%	102,726 $882,000
Q4 2020 Feb 16, 2021	BUY	$12.07 - $17.95 $1.39 Million - $2.06 Million	115,004 Added 974.86%	126,801 $1.54 Million
Q3 2020 Nov 16, 2020	BUY	$14.16 - $19.45 $167,045 - $229,451	11,797 New	11,797 $192,000

13.3M

191K

135K

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $142M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.